[go: up one dir, main page]

EA201300079A2 - Фармацевтическая композиция для пролонгированного высвобождения триметазидина - Google Patents

Фармацевтическая композиция для пролонгированного высвобождения триметазидина

Info

Publication number
EA201300079A2
EA201300079A2 EA201300079A EA201300079A EA201300079A2 EA 201300079 A2 EA201300079 A2 EA 201300079A2 EA 201300079 A EA201300079 A EA 201300079A EA 201300079 A EA201300079 A EA 201300079A EA 201300079 A2 EA201300079 A2 EA 201300079A2
Authority
EA
Eurasian Patent Office
Prior art keywords
trimetazidine
pharmaceutical composition
prolonged delivery
prolonged
delivery
Prior art date
Application number
EA201300079A
Other languages
English (en)
Other versions
EA030227B1 (ru
EA201300079A3 (ru
Inventor
Патрик Женти
Кристоф Эрмелен
Жан-Манюэль Пеан
Original Assignee
Ле Лаборатуар Сервье
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47504206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201300079(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ле Лаборатуар Сервье filed Critical Ле Лаборатуар Сервье
Publication of EA201300079A2 publication Critical patent/EA201300079A2/ru
Publication of EA201300079A3 publication Critical patent/EA201300079A3/ru
Publication of EA030227B1 publication Critical patent/EA030227B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Композиция для пролонгированного высвобождения триметазидина, где внутренняя фаза содержит триметазидин и наружный слой содержит ретардант и антиагломерирующее средство.
EA201300079A 2012-02-03 2013-02-01 Мини-гранулы для пролонгированного высвобождения триметазидина, способ их получения и применение EA030227B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1200322A FR2986431B1 (fr) 2012-02-03 2012-02-03 Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques

Publications (3)

Publication Number Publication Date
EA201300079A2 true EA201300079A2 (ru) 2013-07-30
EA201300079A3 EA201300079A3 (ru) 2013-11-29
EA030227B1 EA030227B1 (ru) 2018-07-31

Family

ID=47504206

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300079A EA030227B1 (ru) 2012-02-03 2013-02-01 Мини-гранулы для пролонгированного высвобождения триметазидина, способ их получения и применение

Country Status (47)

Country Link
US (1) US10117838B2 (ru)
EP (1) EP2623096B1 (ru)
JP (1) JP6338818B2 (ru)
KR (2) KR20130090365A (ru)
CN (2) CN103239425A (ru)
AP (1) AP2013006693A0 (ru)
AR (1) AR089861A1 (ru)
AU (1) AU2013200481B2 (ru)
BR (1) BR102013002524B1 (ru)
CA (1) CA2805471C (ru)
CL (1) CL2013000336A1 (ru)
CO (1) CO6720159A1 (ru)
CR (1) CR20130037A (ru)
CU (1) CU24157B1 (ru)
CY (1) CY1121696T1 (ru)
DK (1) DK2623096T3 (ru)
DO (1) DOP2013000024A (ru)
EA (1) EA030227B1 (ru)
EC (1) ECSP13012415A (ru)
ES (1) ES2735053T3 (ru)
FR (1) FR2986431B1 (ru)
GE (1) GEP20156342B (ru)
GT (1) GT201300032A (ru)
HR (2) HRP20130082A2 (ru)
HU (1) HUE043942T2 (ru)
IL (1) IL224495B (ru)
JO (1) JO3505B1 (ru)
LT (1) LT2623096T (ru)
MD (1) MD4622C1 (ru)
MX (1) MX363302B (ru)
MY (1) MY162599A (ru)
NI (1) NI201300014A (ru)
PE (1) PE20131119A1 (ru)
PH (1) PH12013000031B1 (ru)
PL (1) PL2623096T3 (ru)
PT (1) PT2623096T (ru)
RO (1) RO128004A3 (ru)
RS (2) RS20130034A1 (ru)
RU (1) RU2621128C2 (ru)
SG (1) SG192386A1 (ru)
SI (1) SI2623096T1 (ru)
SV (1) SV2013004396A (ru)
TR (1) TR201906390T4 (ru)
TW (1) TWI508755B (ru)
UA (1) UA118742C2 (ru)
UY (1) UY34595A (ru)
WO (1) WO2013114053A2 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6254719B2 (ja) * 2014-04-08 2017-12-27 ダウ グローバル テクノロジーズ エルエルシー エステル化セルロースエーテルを含む分散体
EP3525771A4 (en) * 2016-11-21 2020-05-27 Saghmos Therapeutics, Inc. PREVENTION AND / OR TREATMENT OF ACUTE RENAL FAILURE INDUCED BY CONTRAST AGENTS
CN109316455B (zh) * 2017-07-31 2021-05-25 北京福元医药股份有限公司 一种盐酸曲美他嗪缓释片
CN110237053A (zh) * 2019-07-26 2019-09-17 湖北欣泽霏药业有限公司 一种盐酸曲美他嗪缓释微丸及其制备方法
KR20250035269A (ko) * 2023-09-05 2025-03-12 주식회사 뉴캔서큐어바이오 트리메타지딘을 포함하는 코팅정 조성물 및 이의 제조방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL122039C (ru) * 1960-10-20
FR2490963B1 (fr) 1980-09-30 1986-04-18 Science Union & Cie Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine
JPH04169522A (ja) * 1990-11-01 1992-06-17 Shin Etsu Chem Co Ltd 徐放性錠剤およびその製造方法
FR2717687B1 (fr) * 1994-03-24 1996-06-14 Adir Compositions pharmaceutiques permettant la libération prolongée de trimétazidine après administration par voie orale.
FR2802424B1 (fr) * 1999-12-17 2002-02-15 Adir Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
PT1195160E (pt) * 2000-10-05 2009-12-07 Usv Ltd Composições farmacêuticas de trimetazidina de libertação sustentada e método para a sua preparação
AU2002356425A1 (en) * 2001-11-21 2003-06-10 Themis Laboratories Private Limited A process for manufacture of a sustained release composition containing microbe
RU2281772C1 (ru) * 2005-02-14 2006-08-20 Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" Лекарственная форма, обладающая антиангинальным действием, и способ ее изготовления
WO2007133583A2 (en) * 2006-05-09 2007-11-22 Mallinckrodt Inc. Zero-order modified release solid dosage forms
CN100571703C (zh) * 2006-12-20 2009-12-23 山东省医药工业研究所 曲美他嗪缓释微丸及其制备方法
CN104739819A (zh) * 2007-11-09 2015-07-01 田边三菱制药株式会社 新型制剂
RU2362548C1 (ru) * 2007-11-20 2009-07-27 Закрытое Акционерное Общество "Канонфарма Продакшн" Матричная таблетка с основой для пролонгированного высвобождения триметазидина дигидрохлорида, способ ее получения и способ лечения
EP2389167A2 (en) * 2009-01-20 2011-11-30 Micro Labs Limited Modified release solid pharmaceutical compositions of trimetazidine and process thereof
ES2567722T3 (es) * 2009-01-30 2016-04-26 Lupin Limited Composiciones farmacéuticas de trimetazidina
EP2408437A1 (en) * 2009-03-18 2012-01-25 Evonik Röhm GmbH Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
EP2394644B1 (en) * 2010-05-04 2014-07-09 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Trimetazidine Formulation With Different Release Profiles
CN102133195A (zh) * 2011-03-17 2011-07-27 王国栋 盐酸曲美他嗪的缓控释微丸及其制备方法

Also Published As

Publication number Publication date
FR2986431B1 (fr) 2017-03-17
WO2013114053A2 (fr) 2013-08-08
IL224495B (en) 2020-08-31
UY34595A (es) 2013-09-02
US10117838B2 (en) 2018-11-06
TW201332591A (zh) 2013-08-16
UA118742C2 (uk) 2019-03-11
EA030227B1 (ru) 2018-07-31
DOP2013000024A (es) 2014-07-15
CA2805471A1 (fr) 2013-08-03
TR201906390T4 (tr) 2019-05-21
CR20130037A (es) 2013-09-18
JP2013159609A (ja) 2013-08-19
SI2623096T1 (sl) 2019-06-28
SG192386A1 (en) 2013-08-30
RS20130034A1 (en) 2013-10-31
LT2623096T (lt) 2019-05-10
MX2013001118A (es) 2013-08-27
CY1121696T1 (el) 2020-07-31
CU24157B1 (es) 2016-03-31
KR101918211B1 (ko) 2018-11-14
RU2013104252A (ru) 2014-08-10
MD4622C1 (ru) 2019-10-31
JP6338818B2 (ja) 2018-06-06
AP2013006693A0 (en) 2013-01-31
RS58752B1 (sr) 2019-06-28
KR20130090365A (ko) 2013-08-13
US20130202710A1 (en) 2013-08-08
HUE043942T2 (hu) 2019-09-30
MD4622B1 (ru) 2019-03-31
MY162599A (en) 2017-06-30
CU20130016A7 (es) 2014-10-02
PH12013000031A1 (en) 2014-09-22
CO6720159A1 (es) 2013-07-31
RO128004A3 (ro) 2013-08-30
CA2805471C (fr) 2018-05-01
AU2013200481B2 (en) 2015-01-22
RU2621128C2 (ru) 2017-05-31
TWI508755B (zh) 2015-11-21
RO128004A0 (ro) 2012-12-28
WO2013114053A3 (fr) 2013-12-19
ES2735053T3 (es) 2019-12-13
JO3505B1 (ar) 2020-07-05
FR2986431A1 (fr) 2013-08-09
SV2013004396A (es) 2013-06-05
PT2623096T (pt) 2019-05-30
PL2623096T3 (pl) 2019-08-30
CL2013000336A1 (es) 2014-07-18
ECSP13012415A (es) 2014-09-30
CN103239425A (zh) 2013-08-14
PE20131119A1 (es) 2013-10-12
PH12013000031B1 (en) 2014-09-22
GT201300032A (es) 2014-06-09
NZ606550A (en) 2014-09-26
HRP20130082A2 (hr) 2013-08-31
KR20150102922A (ko) 2015-09-09
BR102013002524A2 (pt) 2014-09-09
EP2623096A2 (fr) 2013-08-07
CN106924221A (zh) 2017-07-07
GEP20156342B (en) 2015-08-10
DK2623096T3 (da) 2019-07-15
EP2623096B1 (fr) 2019-04-03
AR089861A1 (es) 2014-09-24
NI201300014A (es) 2013-05-13
EP2623096A3 (fr) 2013-10-23
BR102013002524B1 (pt) 2020-02-04
MX363302B (es) 2019-03-20
EA201300079A3 (ru) 2013-11-29
AU2013200481A1 (en) 2013-08-22
MD20130005A2 (ru) 2013-07-31
HRP20191072T1 (hr) 2019-11-01

Similar Documents

Publication Publication Date Title
BR112015002738A2 (pt) composto , e , composição farmacêutica
IL233154A (en) Compounds, pharmaceuticals containing them and their uses
MY163083A (en) Solid forms of a pharmaceutically active substance
DK2736497T3 (da) Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel.
BR112013024267A2 (pt) compostos tricíclicos fundidos substituídos, composições e aplicações medicinais dos mesmos.
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
UY34581A (es) Dispositivo de inhalación para fármacos en polvo
UA110103C2 (ru) Модифицированный туберкулезный антиген
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
BR112014009889A2 (pt) compostos dissubstituídos, compostos e composição farmacêutica
CY1121696T1 (el) Φαρμακευτικη συνθεση παρατεταμενης απελευθερωσης της τριμεταζιδινης
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
CL2014003283A1 (es) Formulación farmacéutica.
BR112015010797A2 (pt) compostos aniônicos substituídos, e, composição farmacêutica
EA201491517A1 (ru) N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
UY34579A (es) Dispositivo de inhalación para fármacos en polvo
EP3039009A4 (en) Mao-b selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof
BR112014032501A2 (pt) composto, e, composição farmacêutica.
CL2015000610A1 (es) Derivados de isoxazolidina
MX372834B (es) PREPARACION FARMACEUTICA COMBINADA QUE COMPRENDE EL BLOQUEANTE DEL RECEPTOR DE LA ANGIOTENSINA II Y EL INHIBIDOR DE LA HMG-CoA REDUCTASA.
FR3012814B1 (fr) Composition polymere comprenant et liberant un compose actif odorant
UY34580A (es) Dispositivo de inhalación para fármacos en polvo
ITTO20121127A1 (it) Procedimento per la protezione di mais.
BR112014016122A2 (pt) composto, e, composição farmacêutica